Evaluation of urinary miRNA-96 as a potential biomarker for bladder cancer diagnosis
Authors:
- 16 December 2014
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 32 (1) , 1-7
Abstract
For bladder cancer, a new diagnostic marker is needed to avoid painful cystoscopy. The aim of this study was to explore the efficacy of urinary miRNA-96 as molecular marker in bladder cancer diagnosis and its relation to bilharziasis. Urine cytology, serologic assessment of schistosomiasis and estimation of miRNA-96 by real-time PCR were carried out for 94 bladder cancer patients, 30 benign bladder lesions and 60 healthy individuals. Expression of miRNA-96 showed a significant difference among the three tested groups and also between benign and malignant bilharzial cases. Urinary miRNA-96 is a good noninvasive diagnostic biomarker for bladder cancer.Keywords
This publication has 22 references indexed in Scilit:
- MiR‐96 and miR‐183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytologyCancer Science, 2010
- Biomarkers in bladder cancerHistopathology, 2010
- MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinomaJournal of Hepatology, 2010
- Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosisCancer Science, 2010
- Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer CellsJournal of Biological Chemistry, 2009
- Genomic Profiling of MicroRNAs in Bladder Cancer: miR-129 Is Associated with Poor Outcome and Promotes Cell Death In vitroCancer Research, 2009
- Should we screen for bladder cancer in a high‐risk population?Cancer, 2006
- Molecular markers in bladder cancer: A critical appraisalUrologic Oncology: Seminars and Original Investigations, 2006
- Unique microRNA molecular profiles in lung cancer diagnosis and prognosisCancer Cell, 2006
- Reactivity ofSchistosoma japonicumandS. mansoniantigen preparations in indirect haemagglutination (IHA) with sera of patients with homologous and heterologous schistosomiasisPathogens and Global Health, 1991